Xylomet

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xylomet

What is Xylomet? An Overview

Here is a quick overview of the key properties of Xylomet:

Property Description
Active ingredient Xylometazoline hydrochloride
Form Nasal drops, nasal spray (Aqueous solution)
Pharmacological class Nasal Decongestant, Sympathomimetic Agent
Common purpose Relieving nasal congestion
Origin Synthetic, Imidazoline derivative

What is Xylomet and What Class Does It Belong To?

Xylomet is the product name for a single-ingredient medication containing Xylometazoline hydrochloride, which is fundamentally classified as a Nasal Decongestant. This compound is a synthetic substance. Chemically, it functions as a sympathomimetic agent and an alpha-adrenergic agonist, meaning it mimics certain effects of the sympathetic nervous system. The agent is characterized by its ability to provide prompt relief.

The classification as an alpha-adrenergic agonist places it within a category of pharmaceutical agents known to directly stimulate vascular receptors. Xylomet is typically available as a widely accessible, single-ingredient, Over-the-Counter (OTC) preparation intended for managing general congestion. Its formulation often targets the adult patient group, distinguishing it from preparations marketed specifically for younger children.


Xylomet's Composition and General Purpose

The active substance, Xylometazoline hydrochloride, is a derivative of Imidazoline and is formulated in an aqueous vehicle (a water-based solution) intended for topical, intranasal application. The medication is commonly supplied in dedicated nasal drops and metered-dose nasal spray solutions.

The primary function of Xylomet is to rapidly cause vasoconstriction (narrowing) of blood vessels within the nasal lining. This effect alleviates symptoms in common scenarios, such as when a person experiences a stuffy nose due to the common cold or hay fever. Xylometazoline acts to decrease the sensation of nasal obstruction by reducing nasal airway resistance. This action ensures the product’s general purpose is achieved: providing effective, symptomatic relief by facilitating an increase in nasal airflow.

Regulatory References

  1. WHO List of Essential Medicines

What side effects are possible with Xylomet?

Possible Side Effects and Safety Information

The safety profile for Xylometazoline, the active ingredient in Xylomet, is structured by regulatory documents based on the potential incidence and nature of adverse reactions. The most commonly reported effects are localized to the area of application.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency in official labeling:

  • Common (may affect up to 1 in 10 people): Local irritation, a burning sensation in the nose and throat, nasal dryness and discomfort, headache, and nausea.
  • Uncommon (may affect up to 1 in 100 people): Nosebleeds (Epistaxis) and an increased swelling of the nasal mucous membranes after discontinuing treatment (Rebound Congestion).
  • Very Rare (may affect up to 1 in 10,000 people): Systemic effects such as arrhythmia (irregular heart rate), tachycardia (increased heart rate), and hypersensitivity reactions (including rash or angioedema). CNS effects like hallucinations and convulsions are also documented as very rare, primarily in children.

Duration-Related Safety Patterns

The phenomenon of Rhinitis Medicamentosa, or rebound congestion, is explicitly associated with prolonged and/or heavy use. This condition involves a return of nasal swelling that is worse than the initial congestion, underscoring a time-dependent constraint on the medicine's use.

Population-Specific Safety Constraints

Official documents define specific restrictions for use. The medicine is contraindicated in patients with conditions such as narrow-angle glaucoma, rhinitis sicca (dry nose), or following trans-sphenoidal hypophysectomy. Caution is advised for individuals with pre-existing conditions like hypertension, severe cardiovascular disorders, diabetes mellitus, and hyperthyroidism. Due to the potential for systemic vasoconstrictor effects, use during pregnancy and lactation requires specific consideration.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Xylometazoline hydrochloride (Xylomet) may occur following excessive nasal application or accidental ingestion, with the potential for serious and life-threatening systemic effects. Regulatory warnings emphasize that children are particularly vulnerable, with even small volumes capable of causing rapid, severe CNS and respiratory depression.

Documented Overdose Manifestations

The official regulatory profile details disturbances in two key systems:

  • Central Nervous System (CNS) effects: Sedation, lethargy, drowsiness, headache, and potentially escalating to coma and convulsions.
  • Cardiovascular effects: Irregular heart rate (tachycardia or bradycardia), and fluctuating blood pressure (initial hypertension followed by subsequent hypotension). Other signs include apnoea (suspension of breathing) and cyanosis.

Urgent Medical Action and Management

Authorities state that immediate emergency medical care must be sought for any suspected overdose or accidental ingestion, and a Poison Control Center should be contacted right away. No specific antidote is known for this substance; therefore, management is based on symptomatic and supportive treatment under medical supervision. Hospital monitoring is required, including the observation of blood pressure, heart rate, and respiratory function, to manage potential severe complications.

Therapeutic Uses of Xylomet

Main Uses and Therapeutic Applications

Xylometazoline, the active ingredient in Xylomet, is a topical nasal decongestant belonging to the sympathomimetic class of medications. It is primarily used to provide temporary relief from nasal congestion associated with various upper respiratory conditions.

Nasal Congestion Relief

The primary function of Xylomet is to alleviate the sensation of a "blocked nose." It is commonly used to manage symptoms arising from:

  • Acute Coryza (Common Cold): Reduces swelling of the nasal mucosa caused by viral infections.
  • Allergic Rhinitis: Eases congestion triggered by environmental allergens such as pollen, dust mites, or pet dander.
  • Sinusitis: Facilitates the drainage of secretions by reducing inflammation at the sinus openings.

Benefits in Clinical Context

Beyond symptomatic relief of the common cold, Xylomet serves specific roles in clinical and diagnostic settings:

  • Facilitation of Nasal Examination: By shrinking the nasal mucosa, it provides a clearer view of the nasal passages during rhinoscopy or other diagnostic procedures.
  • Middle Ear Congestion: It may be used as an adjunct therapy in cases of otitis media to help decongest the nasopharyngeal mucosa, which can assist in opening the Eustachian tubes.

Mechanism of Action and Benefits

Xylomet works by stimulating alpha-adrenergic receptors on the smooth muscles of the nasal blood vessels. This action leads to several physiological benefits:

  • Vasoconstriction: It narrows the dilated blood vessels in the nasal cavity, which reduces blood flow to the area.
  • Reduction of Edema: By decreasing vascular congestion, it reduces the swelling of the mucous membranes.
  • Improved Airflow: The reduction in mucosal thickness increases the diameter of the nasal passages, allowing for easier breathing through the nose.
  • Rapid Onset: The local application allows the medication to begin working within minutes, providing quick relief for the patient.

Eligibility and Restrictions for Use

Population Eligibility and Non-Eligibility for Xylometazoline

The eligibility to use Xylometazoline is defined by official regulatory documents and is governed by strict age limits, co-treatment rules, and pre-existing conditions.

Contraindicated Populations (Must Not Use) The medicine is formally contraindicated in specific patient groups:

  • Children under 2 years of age for all concentrations.
  • Individuals with narrow-angle glaucoma.
  • Patients with specific nasal conditions, such as rhinitis sicca (dry rhinitis) or atrophic rhinitis.
  • Patients currently taking or having taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
  • Individuals who have undergone transsphenoidal hypophysectomy or surgery exposing the dura mater.

Age and Concentration Rules Eligibility is determined by age and the product concentration used: the 0.05% concentration is typically authorized for children aged 2 to 11 years, while the standard 0.1% concentration is intended for adults and adolescents (12 years and over).

Conditional Use (Use with Caution) Use is restricted and requires caution or professional consultation for patients with underlying systemic conditions, including severe cardiovascular disease (e.g., hypertension), diabetes mellitus, hyperthyroidism, prostatic hypertrophy, and phaeochromocytoma. Additionally, use during pregnancy and lactation is generally not recommended and should only proceed under specific medical advice.

What should I know about interactions with other medicines?

Xylometazoline is a topical nasal decongestant that is generally considered safe when used as directed. However, due to its sympathomimetic properties (meaning it mimics the effects of the body's natural adrenaline-like substances), systemic absorption can occasionally lead to clinically significant interactions with certain medications. It is essential to inform your healthcare provider about all medicines you are taking, including over-the-counter products.

Major Interactions

Monoamine Oxidase Inhibitors (MAOIs): Xylometazoline should not be used concurrently with MAOIs (a class of antidepressants) or within 14 days of stopping their use. This combination can lead to a severe increase in blood pressure (hypertensive crisis) due to a synergistic effect on catecholamine levels.

Drug Class Potential Interaction Risk Level
MAO Inhibitors Severe hypertension (hypertensive crisis) High (Contraindicated)

Significant Interactions Requiring Caution

Tricyclic and Tetracyclic Antidepressants: Concomitant use with these antidepressants may increase the effect of Xylometazoline on the cardiovascular system, potentially leading to increased blood pressure and heart rate (tachycardia). Close monitoring is advised.

Anti-Hypertensive Agents: The vasoconstrictive action of Xylometazoline may theoretically reduce the effectiveness of medicines used to lower blood pressure, such as beta-blockers.

Consult your doctor or pharmacist if you are taking any of these medications to assess the risk-benefit and determine if an alternative treatment is necessary.

Mechanism of Action

Xylomet functions as a selective agonist of alpha-adrenergic receptors. Following topical application, the molecule targets receptors located on the vascular smooth muscle cells within the nasal mucosa. It exhibits a high affinity for stimulating the alpha2 adrenergic receptor subtype.

Activation of these receptors initiates a signal transduction cascade that induces the contraction of the smooth muscle. This cellular response results in the constriction of the arterioles, capillaries, and veins within the nasal passages (vasoconstriction), which subsequently restricts the flow of blood to the mucosal tissue. The decreased local blood volume acts to reduce the hydrostatic pressure within the microcirculation, thereby lessening the efflux of fluid into the interstitial space. This physiological modulation leads to a decrease in tissue edema and inflammation within the nasal passages.

Dosage and Administration Information

Instruction Map: How to use Xylomet — Administration Guidelines

The following details outline the standard protocols for the safe and correct use of Xylometazoline (Xylomet).


Administration Scope

  • Route of administration: Nasal (Intranasal) use only.
  • Timing in relation to meals (if applicable): Not applicable. The final dose of the day should preferably be administered shortly before retiring to bed.
  • Preparation requirements (if applicable): Before first use or after a long interruption, prime the spray pump several times away from the face until an even, fine mist emerges. For subsequent doses, the device is immediately ready for use.

Dosing Rules

Age Group Strength Dose per Nostril Frequency Max Duration
Adults & Children ge 12 years 0.1% solution 2–3 drops or 1-2 sprays Up to 3 times per day le 7 consecutive days
Children 6–12 years 0.05% solution 1–2 drops or sprays Up to 3 times per day le 5 to 7 consecutive days
Children < 6 years Not recommended Use and dose must be determined by a physician Consult physician Consult physician
  • Frequency Constraint: Doses should typically be separated by an interval of 8 to 10 hours. Do not exceed the maximum of 3 applications in any 24-hour period.
  • Missed-dose rules: If a dose is missed, skip the missed dose and resume the regular dosing schedule. Do not use a double dose to compensate for a forgotten dose.
  • Special procedural conditions: Blow the nose thoroughly before application. For hygienic reasons and to avoid spreading infection, each container must only be used by one person. Do not use for longer than the recommended short duration to prevent rebound congestion.

Connection to the Overall Use Protocol

The instructions establish a topical nasal administration protocol defined by age-specific concentrations (0.1% vs. 0.05%) and a limit on daily dose frequency and overall duration of use. The process requires a mandatory priming step for the spray device and strict hygienic practices to ensure correct delivery and prevent potential cross-contamination. This structured use protocol defines the parameters for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xylomet


Evidence for Acute Nasal Congestion Caused by the Common Cold

The primary research structure for this use includes short-term, randomized controlled trials (RCTs), often comparing Xylomet against a placebo in adults with congestion associated with a cold. Researchers monitored participants during studies conducted during periods of increased symptom activity and recorded objective measurements of nasal airflow, as well as patient-reported outcomes describing perceived discomfort. Findings described measurements related to physical discomfort and monitored the rate at which nasal airflow measurements evolved. This evidence contributes to understanding short-term changes under the specific conditions of the trials.


Evidence for Acute Nasal Congestion Associated with Allergic Rhinitis

Research examining this indication includes some randomized trials and reviews of scientific literature, often focused on conditions characterized by fluctuating or episodic manifestations like allergic rhinitis. Studies examined outcomes related to physical discomfort during symptomatic episodes. Findings indicated patterns in congestion measurements related to mucosal swelling caused by allergens. However, the volume and design of the evidence for this indication differs from the common cold research, and evidence regarding its role in the long-term management of allergic symptoms is not fully established.


Key Research Limitations and Evidence Gaps

Across all indications, the follow-up durations were limited, typically restricted to the acute treatment period of up to 7 to 10 days. Therefore, long-term effects are not fully established beyond the acute phase, and research provides context but not individual predictions about outcomes from chronic use. Additionally, data for certain groups remain insufficient, as the majority of studies involved healthy adults, leaving subgroup findings uncertain for older adults or those with specific comorbidities.

Key Studies & References

  1. Rhinitis Medicamentosa - StatPearls (NIH)

Frequently Asked Questions (FAQ)

Common questions about Xylomet (FAQ)


Q: Is Xylomet the same thing as other popular nasal sprays?

Xylomet contains the active ingredient Xylometazoline, which belongs to a class of medications called alpha-adrenergic agonists used as nasal decongestants. While other popular nasal sprays, like those containing oxymetazoline or phenylephrine, belong to the same sympathomimetic group, they are recognized by regulatory bodies as distinct chemical substances.

Q: Is it normal to feel a stinging or burning sensation right after using Xylomet?

According to the official product information, feeling a stinging or burning sensation in the nose and throat is listed as a common side effect. Regulatory documents indicate this may affect up to 1 in 10 people. Nasal dryness and local irritation are also listed as common effects.

Q: Can children use Xylomet, and if so, what age is appropriate?

Eligibility is based on age and concentration. Children 6 to 12 years old may use a lower strength 0.05% solution. The product is generally not recommended for children under 6 years due to potential risks, and use in children under 2 is strictly contraindicated.

Q: Is Xylomet safe for use during pregnancy or while breastfeeding?

Official regulatory information states that use during pregnancy and lactation (breastfeeding) is generally not recommended. Use during these periods generally requires specific medical consultation to assess risks and benefits.

Q: What are the most common mild side effects of Xylomet?

The most common mild side effects, according to regulatory adverse reaction classifications, include localized effects such as nasal dryness, local irritation, and a burning sensation in the nose and throat. Other common effects include headache and nausea.

Q: Can Xylomet be used with other cold and flu medications?

Official warnings emphasize that Xylomet should not be used with specific medications like Monoamine Oxidase Inhibitors (MAOIs), tricyclic antidepressants, and certain anti-hypertensive agents. If you are taking common cold or flu medicines, consulting a healthcare professional is advisable, as general interactions are not universally ruled out.

Q: What medical conditions would prevent someone from using Xylomet?

The medicine is contraindicated (must not be used) in people with certain conditions, including narrow-angle glaucoma and specific nasal issues like rhinitis sicca (dry rhinitis). Caution is also specifically advised for individuals with pre-existing conditions like severe cardiovascular disorders, hypertension, diabetes mellitus, and hyperthyroidism.

Q: Does Xylomet cause drowsiness, making it unsafe to drive?

Drowsiness and other Central Nervous System (CNS) effects are listed in regulatory documents as very rare side effects, mostly reported in children or in cases of overdose. Patients should be aware of the potential for rare CNS effects before operating machinery or driving.

Q: Does Xylomet contain steroids or corticosteroids?

No. Xylomet does not contain steroids or corticosteroids. Its active substance is Xylometazoline hydrochloride, which is officially classified as a Nasal Decongestant and an alpha-adrenergic agonist.

Q: Does Xylomet affect my ability to fall asleep at night?

Official instructions suggest that the final daily dose should be administered shortly before retiring to bed. However, because Xylomet is a sympathomimetic agent (mimics adrenaline-like effects), insomnia (difficulty sleeping) is listed as a very rare potential adverse effect in regulatory documents.

Q: Are there different formulas of Xylomet for adults versus children?

Yes, different concentrations are regulated for different age groups. The standard 0.1% concentration is for adults and adolescents (ge 12 years), while the lower strength 0.05% solution is used for children (6-12 years), reflecting the different regulatory guidelines for age groups.

Q: Why do some people say Xylomet is addictive?

Regulatory warnings acknowledge the risk of dependency in the form of Rebound Congestion (Rhinitis Medicamentosa). This is a condition where nasal swelling worsens after stopping the medicine due to prolonged and/or heavy use. This phenomenon underscores the importance of adhering to the recommended short duration of use.

Q: What happens if I accidentally swallow some of the Xylomet spray?

If the drug is accidentally swallowed, especially by a child, systemic absorption may occur, potentially leading to signs of overdose. These effects can include cardiovascular symptoms like tachycardia (increased heart rate) and CNS depression (drowsiness). Professional medical attention may be required.

Q: How long does the congestion relief from Xylomet typically last?

Based on official monographs and drug data, Xylomet is known for its fast onset of action. The decongestant effect typically lasts for a duration of 6 to 8 hours before the next application.

Q: Is Xylomet effective for chronic sinus issues?

The product is indicated for the temporary symptomatic treatment of nasal congestion associated with acute conditions like colds or allergies. The maximum recommended duration of use is strictly limited to 7 consecutive days, indicating it is intended only for acute, short-term symptom management.

Q: Why does Xylomet sometimes cause a dry nose or throat?

Xylomet works by causing vasoconstriction, which narrows the blood vessels in the nasal lining. This action reduces blood flow to the mucosa, which can lead to reduced moisture. This effect is documented as a common side effect, presenting as dryness or a burning sensation.

Q: Is Xylomet effective against congestion caused by non-allergic rhinitis?

The approved indications are for the temporary symptomatic relief of nasal congestion due to rhinitis. This term broadly covers conditions of nasal inflammation, including those caused by both allergic factors (hay fever) and non-allergic factors.

Q: Are there any long-term effects of using Xylomet occasionally?

Official regulatory studies have generally been restricted to short-term follow-up, typically 7 to 10 days. Therefore, the effects of occasional or intermittent use extending over a long period are not fully established by regulatory research.

Q: Can Xylomet be used to treat ear congestion?

The approved and regulated indications are specifically for temporary symptomatic treatment of nasal congestion. While the active ingredient may theoretically influence the eustachian tube, treating ear congestion is not an approved indication for this product.

Q: Do you have to clear your nose before using Xylomet?

Yes. Official administration guidelines advise that the user blow the nose thoroughly before application to ensure the medicine can effectively reach the nasal lining for proper absorption and action.

Q: Is there an equivalent generic version of Xylomet?

Xylomet is the brand name for the active ingredient, Xylometazoline hydrochloride. This active chemical substance is widely available in many countries as a generic medication under various names.

Q: What should I do if I think I've used too much Xylomet?

If you suspect an overdose, which can cause symptoms like cardiovascular effects or CNS changes (e.g., extreme drowsiness), professional medical assistance should be sought immediately. Regulatory guidelines document that intoxication can occur, especially with high systemic absorption.

Q: Can Xylomet raise blood sugar levels in diabetic patients?

Yes, official safety information indicates that because Xylomet is a sympathomimetic agent, it may cause slight increases in blood glucose concentrations. The product is generally required to be used with caution in patients with diabetes mellitus.

Q: What does the package insert say about Xylomet and thyroid conditions?

Regulatory documents advise that caution should be exercised when the product is used by individuals with hyperthyroidism (an overactive thyroid). This is due to the potential for the medicine's systemic absorption to cause sympathomimetic effects.

Q: Does Xylomet cause problems for people with glaucoma?

Yes, Xylomet is formally contraindicated and must not be used by patients diagnosed with narrow-angle glaucoma. This restriction is in place due to the risk of systemic absorption causing a rise in intraocular pressure.

Q: Can using Xylomet cause nosebleeds?

Nosebleeds, or Epistaxis, are documented as an uncommon side effect in the official product labeling. This means that they may affect up to 1 in 100 people who use the medication.

Q: Is there a special technique for using the nasal spray correctly?

Yes, correct usage requires certain steps. For example, before the first use, correct use requires that the spray pump be primed until a fine mist appears. Additionally, for hygienic reasons and to prevent infection, each container should only be used by one person.

Q: Does Xylomet interact with stimulant medications like those for ADHD?

Regulatory documents explicitly warn against the use of Xylomet with certain antidepressants (MAOIs and tricyclics) due to increased cardiovascular risk. Since it is a sympathomimetic drug, consultation with a healthcare professional is important before use with other stimulant classes.

Q: Can Xylomet cause anxiety or nervousness?

Official adverse reaction lists include nervousness and anxiety as very rare potential side effects. More severe Central Nervous System (CNS) effects, such as hallucinations or convulsions, are also documented as very rare, primarily in children.

Q: What if I forget a dose of Xylomet—should I just wait for the next one?

Official regulatory instructions for a missed dose advise users to skip the forgotten dose and then resume the regular dosing schedule. It is explicitly stated that a double dose should not be used to try and make up for a missed application.

How should Xylomet be stored and disposed of?

Storage and Disposal Conditions for Xylometazoline

The storage of xylometazoline nasal products must adhere to specific regulatory conditions to maintain stability and safety.

Storage Requirements

The medicine is required to be stored at Controlled Room Temperature, typically defined as 20 °C to 25 °C (68 °F to 77 °F), and must not freeze. It must be protected from light and stored in a dry place. The container must be kept tightly closed, and the contents must be used within 28 days after first opening the package.

Child Safety and Disposal

A mandatory instruction requires the product to be stored out of the sight and reach of children. Regarding disposal, the product should not be disposed of via wastewater or household waste; instead, unused medicine or waste material must be handled in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xylomet found in:

A-Z Index: